Quantum BioPharma Ltd. (QNTM)
NASDAQ: QNTM · Real-Time Price · USD
15.99
+0.80 (5.27%)
At close: Oct 14, 2025, 4:00 PM EDT
16.00
+0.01 (0.06%)
After-hours: Oct 14, 2025, 7:54 PM EDT
Quantum BioPharma Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
17
Market Cap
61.14M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | - | - | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 422.82B |
| Johnson & Johnson | 90.63B |
| Merck & Co. | 63.62B |
| AbbVie | 58.33B |
| AstraZeneca | 56.50B |
| Novartis AG | 55.19B |
| Eli Lilly and Company | 53.26B |
| Novo Nordisk | 49.11B |
QNTM News
- 18 hours ago - Quantum BioPharma Ltd. Responds to Vague and Misleading Allegations by The Schall Law Firm and DJS Law Group - GlobeNewsWire
- 5 days ago - Quantum BioPharma Ltd. Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights – QNTM - Business Wire
- 5 days ago - QNTM Investors Have Opportunity to Join Quantum BioPharma Ltd. Fraud Investigation with the Schall Law Firm - Business Wire
- 6 days ago - Quantum BioPharma Announces Cash Reward of up to USD $7Million for Proof of Market Manipulation in its Stock - GlobeNewsWire
- 7 days ago - Quantum BioPharma: Engineering the Digital Balance Sheet in Life Sciences A Vanderbilt Report View - Accesswire
- 11 days ago - Quantum BioPharma Announces the Record Date for the Distribution of a Special Dividend of Contingent Value Rights (CVRs) Tied to the Future Litigation Settlement Proceeds of its USD $700 Million+ Case - GlobeNewsWire
- 12 days ago - Quantum BioPharma Receives Final Reports for Two Key Studies of its Potential Breakthrough Drug for Multiple Sclerosis, Moving Closer to Phase 2 Clinical Trial - GlobeNewsWire
- 13 days ago - Quantum BioPharma Welcomes World-Renowned Multiple Sclerosis Expert Dr. Jack Antel as Clinical Development Advisor For Lucid-MS Trials - GlobeNewsWire